Advertisement

Pharmaka mit Wirkung auf das vegetative System

  • E. Oberdisse
Part of the Springer-Lehrbuch book series (SLB)

Zusammenfassung

Die Zellkörper der präganglionären parasympathischen Neurone liegen im Hirnstamm und im Rükkenmark. Efferente parasympathische Fasern des Hirnstamms laufen in einigen Hirnnerven (III., V., VII., IX.) zu den Effektorzellen des Kopfes und im N. vagus zu den Organen im Brust- und Bauchbereich, während die Fasern aus dem Sacralmark im N. pelvicus zu den Organen des Beckens gelangen. Die ganglionäre Umschaltung erfolgt in der Nähe der innervierten Organe, so daß die präganglionären Fasern sehr lang, die postganglionären jedoch kurz sind (Abb. 2.1).

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Amara SG, Kuhar MJ (1994) Neurotransmitter transporters: Recent progress. Annu Rev Neurosci 16:73–93CrossRefGoogle Scholar
  2. Atlas D (1991) Clonidine-displacing substance (CDS) and its putative imidazoline receptor. Biochem Pharmacol 41:1541–1549PubMedCrossRefGoogle Scholar
  3. Barrantes FJ (1993) Structural-functional correlates of the nicotinic acetylcholine receptor and its lipid microenvironment. FASEB J 7:1460–1467PubMedGoogle Scholar
  4. Berde B, Schild HO (eds) (1978) Ergot alkaloids and related compounds. In: Handbook of experimental pharmacology, vol 49. Springer, Berlin Heidelberg New YorkGoogle Scholar
  5. Berde B, Stürmer E (1978) Introduction to the pharmacology of ergot alkaloids and related compounds as a basis of their therapeutic application. In: Berde B, Schild HO (Hrsg) Handbuch der experimentellen Pharmakologie, Bd 49: Ergot alkaloids and related compounds. Springer, Berlin Heidelberg New York, S. 1–28Google Scholar
  6. Boulet L-P (1984) Long- versus short-acting β2-agonists: Implications for drug therapy. Drugs 47:207–222CrossRefGoogle Scholar
  7. Brücke T, Wenger T, Podreka I, Asenbaum S (1991) Dopamine receptor classification, neuroanatomical distribution and in vivo imaging. Wien Klin Wochenschr 103:639–646PubMedGoogle Scholar
  8. Bylund DB (1992) Subtypes of α1- and α2-adrenergic receptors. FASEB J 6:832–839PubMedGoogle Scholar
  9. Caulfield MP (1993) Muscarinic receptors — characterization, coupling and function. Pharmacol Ther 58:319–379PubMedCrossRefGoogle Scholar
  10. Civelli O, Bunzow JR, Grandy DK (1993) Molecular diversity of the dopamine receptors. Annu Rev Pharmacol Toxicol 32:281–307CrossRefGoogle Scholar
  11. Cooper KL, McKiernan JM, Kaplan SA (1999) α-Adrenoceptor antagonists in the treatment of benign prostatic hyperplasia. Drugs 57:9–17PubMedCrossRefGoogle Scholar
  12. Cullumbine H (1967) Muscarinic blocking drugs. Physiol Pharmacol 3:322–362Google Scholar
  13. Diener H-C, May A (1994) Schmerztherapie bei chronischem Kopfschmerz und Migräne. Internist 35:26–31PubMedGoogle Scholar
  14. Eglen RM, Reddy H, Watson N, Challiss RAJ (1994) Muscarinic acetylcholine receptor subtypes in smooth muscle. Trends Pharmacol Sci 15:114–119PubMedCrossRefGoogle Scholar
  15. Emorine L, Blin N, Strosberg AD (1994) The human β3-adrenoceptor: The search for a physiological function. Trends Pharmacol Sci 15:3–7PubMedCrossRefGoogle Scholar
  16. Froehner SC (1993) Regulation of ion channel distribution at synapses. Annu Rev Neurosci 16:347–368PubMedCrossRefGoogle Scholar
  17. Fulton B, Wagstaff AJ, Sorkin EM (1995) Doxazosin: An update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia. Drugs 49:295–320PubMedCrossRefGoogle Scholar
  18. Galzi J-L, Revah F, Bessis A, Changeux J-P (1991) Functional architecture of the nicotinic acetylcholine receptor: From electric organ to brain. Annu Rev Pharmacol Toxicol 31:37–72PubMedCrossRefGoogle Scholar
  19. Ganten D, Mulrow PJ (eds) (1990) Pharmacology of antihypertensive therapeutics. In: Handbook of experimental pharmacology, vol 93. Springer, Berlin Heidelberg New York TokyoGoogle Scholar
  20. Garcia-Sainz JA (1993) α1-adrenergic action: receptor subtypes, signal transduction and regulation. Cell Sign 5:539–547CrossRefGoogle Scholar
  21. Gingrich JA, Caron MG (1993) Recent advances in the molecular biology of dopamine receptors. Annu Rev Neurosci 16:299–321PubMedCrossRefGoogle Scholar
  22. Goyal RK (1989) Muscarinic receptor suptypes: Physiology and clinical implications. New Engl J Med 321:1022–1029PubMedCrossRefGoogle Scholar
  23. Greenblatt DJ, Shader RI (1973) Anticholinergics. New Engl J Med 290:1215–1219CrossRefGoogle Scholar
  24. Hall JM (1992) Bradykinin receptors: Pharmacological properties and biological roles. Pharmacol Ther 56:131–190PubMedCrossRefGoogle Scholar
  25. Hamilton CA (1992) The role of imidazoline receptors in blood pressure regulation. Pharmacol Ther 54:231–248PubMedCrossRefGoogle Scholar
  26. Harrison JK, Pearson WR, Lynch KR (1991) Molecular characterization of α1 - and α2-adrenoceptors. Trends Pharmacol Sci 12:62–67PubMedCrossRefGoogle Scholar
  27. Hebb C (1972) Biosynthesis of acetylcholine in nervous tissue. Physiol Rev 53:918–957Google Scholar
  28. Holmes B, Sorkin EM (1986) Indoramin: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and related vascular, cardiovascular and airway diseases. Drugs 31:467–499PubMedCrossRefGoogle Scholar
  29. Holzgrabe U (1993) Struktur der Acetylcholinesterase. DAZ 133:31–32Google Scholar
  30. Hosey MM (1992) Diversity of structure, signaling and regulation within the family of muscarinic cholinergic receptors. FASEB J 6:845–852PubMedGoogle Scholar
  31. Hucho F, Järv J, Weise C (1991) Substrate-binding sites in acetylcholinesterase. Trends Pharmacol Sci 12:422–426PubMedCrossRefGoogle Scholar
  32. Jahn R, Südhoff TC (1994) Synaptic vesicles and exocytosis. Annu Rev Neurosci 17:219–246PubMedCrossRefGoogle Scholar
  33. Jankovic J, Brin MF (1991) Therapeutic uses of botulinum toxin. New Engl J Med 324:1186–1194PubMedCrossRefGoogle Scholar
  34. Johnson JP (1992) Cellular mechanisms of actions of mine-ralocorticoid hormones. Pharmacol Ther 53:1–29PubMedCrossRefGoogle Scholar
  35. Karczmer AG (1967) Pharmacologic, toxicologic and therapeutic properties of anticholinesterase agents. Physiol Pharmacol 3:163–322Google Scholar
  36. Kharkevich DA (ed) (1980) Pharmacology of ganglionic transmission. In: Handbook of experimental pharmacology, vol 53. Springer, Berlin Heidelberg New YorkGoogle Scholar
  37. Kobilka B (1992) Adrenergic receptors as models for G protein-coupled receptors. Annu Rev Neurosci 15:87–114PubMedCrossRefGoogle Scholar
  38. Kosterlitz HW (1967) Effects of choline esters on smooth muscle and secretions. Physiol Pharmacol 3:97–161Google Scholar
  39. Laduron PM (1985) Presynaptic heteroceptors in regulation of neuronal transmission. Biochem Pharmacol 34:467–470PubMedCrossRefGoogle Scholar
  40. Langtry HD, Mammen GJ, Sorkin EM (1989) Urapidil: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of hypertension. Drugs 38:900–940PubMedCrossRefGoogle Scholar
  41. Li G, Regunathan S, Barrow CJ, Eshraghi J, Cooper R, Reis DJ (1994) Agmatine: An endogenous clonidine-displacing substance in the brain. Science 263:966–969PubMedCrossRefGoogle Scholar
  42. MacKinnon AC, Spedding M, Brown CM (1994) α2-adrenoceptors: More subtypes but fewer functional differences. Trends Pharmacol Sci 15:119–123PubMedCrossRefGoogle Scholar
  43. Marrs TC (1993) Organophosphate poisoning. Pharmacol Ther 58:51–66PubMedCrossRefGoogle Scholar
  44. McDevitt DG (1979) Adrenoceptor blocking drugs: Clinical pharmacology and therapeutic use. Drugs 17:267–288PubMedCrossRefGoogle Scholar
  45. McTavish D, Campoli-Richards D, Sorkin EM (1993) Carvedilol: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 45:232–258PubMedCrossRefGoogle Scholar
  46. Michel MC (1993) Adrenozeptorsubtypen — Funktion und Bedeutung. Med Monatschr Pharm 16:130–136Google Scholar
  47. Minneman KP, Esbenshade TA (1994) α1-adrenergic receptor Subtypes. Annu Rev Pharmacol Toxicol 34:117–133PubMedCrossRefGoogle Scholar
  48. Molderings GJ, Göthert M, Christen O, Schäfer SG (1993) Imidazolrezeptoren und Blutdruckregulation. Dtsch Med Wochenschr 118:953–958PubMedCrossRefGoogle Scholar
  49. Molderings GJ, Michel MC, Göthert M, Christen O, Schäfer SG (1992) Imidazolrezeptoren: Angriffsort einer neuen Generation von antihypertensiven Arzneimitteln. Dtsch Med Wochenschr 117:67–71PubMedCrossRefGoogle Scholar
  50. Molinoff PB (1984) α- and β-adrenergic receptor subtypes. Properties, distribution and regulation. Drugs 28 [Suppl 2]:1–15PubMedCrossRefGoogle Scholar
  51. Morgan T (1994) Clinical pharmacokinetics and pharmacodynamics of Carvedilol. Clin Pharmacokinet 26:335–346PubMedCrossRefGoogle Scholar
  52. Muntz KH, Zhao MM, Miller JC (1994) Downregulation of myocardial β-adrenergic receptors: Receptor subtype selectivity. Circulation Res 74:369–375PubMedGoogle Scholar
  53. Nelson HS (1995) β-adrenergic bronchodilators. New Engl J Med 333:499–506PubMedCrossRefGoogle Scholar
  54. O’Connor SE (1992) Recent developments in the classification and functional significance of receptors for ATP and UTP, evidence for nucleotide receptors. Life Sci 50:1657–1664PubMedCrossRefGoogle Scholar
  55. Ostrowski J, Kjelsberg MA, Caron MG, Lefkowitz RJ (1992) Mutagenesis of the β2-adrenergic receptor: How structure elucidates function. Annu Rev Pharmacol Toxicol 32:167–183PubMedCrossRefGoogle Scholar
  56. Rand MJ, Stafford A (1967) Cardiovascular effects of choline esters. Physiol Pharmacol 3:1–95Google Scholar
  57. Reynolds GP (1996) The importance of dopamine D4 receptors in the action and development of antipsychotic agents. Drugs 51:7–11PubMedCrossRefGoogle Scholar
  58. Ruffolo RR Jr (1991) Chirality in α- and β-adrenoceptor agonists and antagonists. Tetrahedron 47:9953–9980CrossRefGoogle Scholar
  59. Ruffolo RR Jr, Hieble JP (1994) α-adrenoceptors. Pharmacol Ther 61:1–64PubMedCrossRefGoogle Scholar
  60. Ruffolo RR Jr, Nichols AJ, Stadel JM, Hieble JP (1993) Pharmacologic and therapeutic applications of α2-adrenoceptor subtypes. Annu Rev Pharmacol Toxicol 32: 243–279CrossRefGoogle Scholar
  61. Ruffolo RR Jr, Stadel JM, Hieble JP (1994) Alpha-adrenoceptors: Recent developments. Med Res Rev 14: 229–270PubMedCrossRefGoogle Scholar
  62. Sargent PB (1993) The diversity of neuronal nicotinic acetylcholine receptors. Annu Rev Neurosci 16:403–443PubMedCrossRefGoogle Scholar
  63. Schröder HJ (1992) Immunohistochemistry of cholinergic receptors. Anat Embryol 186:407–429PubMedCrossRefGoogle Scholar
  64. Schwartz J-C, Giros B, Martres M-P, Sokoloff P (1992) The dopamine receptor family: Molecular biology and pharmacology. Neurosci 4:99–108Google Scholar
  65. Sibley DR, Monsma FJ Jr (1992) Molecular biology of dopamine receptors. Trends Pharmacol Sci 13:61–69PubMedCrossRefGoogle Scholar
  66. Simpson LL (1974) The use of neuropoisons in the study of cholinergic transmission. Annu Rev Pharmacol 14:305–317CrossRefGoogle Scholar
  67. Sokoloff P, Schwartz J-C (1995) Novel dopamine receptors half a decade later. Trends Pharmacol Sci 16:270–275PubMedCrossRefGoogle Scholar
  68. Sokoloff P, Martres M-P, Giros B, Bouthenet M-L, Schwartz J-C (1992) The third dopamine receptor (D3) as a novel target for antipsychotics. Biochem Pharmacol 43:659–666PubMedCrossRefGoogle Scholar
  69. Soreq H, Gnatt A, Loewenstein Y, Neville LF (1992) Excavations into the active-site gorge of cholinesterases. Trends Biochem Sci 17:353–358PubMedCrossRefGoogle Scholar
  70. Stanaszek WF, Kellermann D, Brogden RN, Romankiewicz JA (1983) Prazosin update: A review of its pharmacological properties and therapeutic use in hypertension and congestive heart failure. Drugs 25:339–384PubMedCrossRefGoogle Scholar
  71. Strochitzky K, Lindner W, Klein W (1994) Chiral aspects of β-adrenoceptor antagonists. Trends Pharmacol Sci 15:102CrossRefGoogle Scholar
  72. Szekeres L (ed) (1980,1981) Adrenergic activators and inhibitors I and II. In: Handbook of experimental pharmacology, vol 54/I and 54/II. Springer, Berlin Heidelberg New YorkGoogle Scholar
  73. Timble WS, Linial M, Scheller RH (1991) Cellular and molecular biology of the presynaptic nerve terminal. Annu Rev Neurosci 14:93–122CrossRefGoogle Scholar
  74. Titmarsh S, Monk JP (1987) Terazosin: A review of its pharmacodynamic and pharmacokinetik properties, and therapeutic efficacy in essential hypertension. Drugs 33:461–477PubMedCrossRefGoogle Scholar
  75. Trendelenburg U, Weiner N (eds) (1988, 1989) Catecholamines I and II. In: Handbook of experimental pharmacology, vol 90/I and 90/II. Springer, Berlin Heidelberg New YorkGoogle Scholar
  76. Wess J (1993) Molecular basis of muscarinic acetylcholine receptor function. Trends Pharmacol Sci 14:308–313PubMedCrossRefGoogle Scholar
  77. Whittaker VP (ed) (1988) The cholinergic synapse. In: Handbook of experimental pharmacology, vol 86. Springer, Berlin Heidelberg New YorkGoogle Scholar
  78. Wood AJJ (1993) Drug therapy of migraine. N Engl J Med 329:1476–1483CrossRefGoogle Scholar
  79. Young RA, Brogden RN (1988) Doxazosin: A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in mild or moderate hypertension. Drugs 35:525–541PubMedCrossRefGoogle Scholar
  80. Zwieten PA van (1993) An overview of the pharmacodynamic roperties and therapeutic potential of combined α- and -adrenoceptor antagonists. Drugs 45:509–517PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1999

Authors and Affiliations

  • E. Oberdisse

There are no affiliations available

Personalised recommendations